1 March 2015 in Journal of Vascular Surgery
3 April 2017 in Journal of Pain & Palliative Care Pharmacotherapy
In the field of interventional pain medicine a radiocontrast agent is commonly used in conjunction with fluoroscopy. Limited work has been published regarding the use of gadolium based contrast agents (GBCA) in the intrathecal space. We report a case of an intrathecal gadobutrol injection resulting in neurotoxic manifestations.A 60-year-old female with a history significant for lumbar post-laminectomy syndrome and intrathecal drug delivery implantation was admitted for lumbar fusion and kyphoplasty. Postoperatively, the patient had escalating pain medication requirements. A pump and intrathecal catheter contrast study was completed to assess the integrity and proper placement of the intrathecal catheter. Due to patient.s allergy to iodinated contrast, the physician requested gadolinium contrast dye. Unknown to the staff was that Magnevist had recently been replaced with an alternative GBCA, Gadavist (gadobutrol). 2 cc of Gadavist was injected. The catheter was determined to be intact and in proper position. Less than five minutes after the injection of gadobutrol, the patient reported spastic pain of the lower extremities. There is a lack of evidence as it relates to the use of GBCA specifically gadobutrol in the intrathecal space. The use of gadobutrol in the intrathecal space should be used with caution.
1 February 2018 in Annals of Vascular Surgery
1 May 2015 in Journal of Vascular Surgery
1 June 2016 in Journal of Trauma and Acute Care Surgery
Resuscitative endovascular balloon occlusion of the aorta (REBOA) has emerged as an alternative to gauze packing (GP) in the setting of non-compressible torso hemorrhage (NCTH). Our objective was to describe placement and physiologic impact of a novel REBOA device during uncontrolled junctional hemorrhage. We hypothesized that REBOA could be deployed without fluoroscopic guidance or intraaortic barotrauma, and increase survival in the setting of profound shock physiology.Fourteen adult swine (35-50kg) underwent a hemorrhage and ischemia/reperfusion injury protocol to produce shock physiology and dilutional coagulopathy and randomized to REBOA (N=8) vs standard gauze packing (GP) (N=6) groups. A complex contralateral groin soft tissue and vascular injury was then created, followed by 30 sec of free bleeding and gauze packing for 5 min. REBOA group had the aortic balloon inflated in aortic zone III until the pressure release valve opened followed by 45 minutes post-packing survival, after which native and balloon-exposed aortae were harvested for histologic analysis.Control and REBOA groups had similar baseline hemodynamics (MAP 32 vs 43 mmHg, p=0.228) levels of coagulopathy (INR 1.3 vs 1.2, p=0.476; fibrinogen 108 vs 135 mg/dl, p=0.747) and hemorrhage/ischemia/reperfusion insult (lactate 7 vs 7, p=0.950 ; BD 9 vs 5, p=0.491). No histologic barotrauma was identified and 88% of REBOA devices were successfully deployed into zone III of the aorta. REBOA group had significantly decreased hemorrhage volumes (0.5 vs 0.2 L, p=0.014) and increased survival times (45 vs 8 min, p<0.001).This study reinforces results found in previous studies that REBOA is an effective method to increase survival in the setting of NPTH and is the first to show that this specific REBOA device can be blindly guided into the appropriate zone of the aorta without generating aortic wall injury during unmeasured balloon inflation.III therapeutic STUDY DESIGN: Original Article.
1 May 2021 in Annals of Vascular Surgery